Warfarin use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer

References

• Schulman S, Lindmarker P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. N Engl J Med 2000;342:1953–8.
   PubMed Web of Science ®Google Scholar
• Baron JA, Gridley G, Weiderpass E, Nyren O, Linet M. Venous thromboembolism and cancer. Lancet 1998;351:1077–80.
   PubMed Web of Science ®Google Scholar
• Kakkar AK, Macbeth F. Antithrombotic therapy and survival in patients with malignant disease. Br J Cancer 2010;102:S24–9.
   PubMed Web of Science ®Google Scholar
• Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer 2011;11:123–34.
   PubMed Web of Science ®Google Scholar
• Battinelli EM, Markens BA, Kulenthirarajan RA, Machlus KR, Flaumenhaft R, Italiano JE. Jr. Anticoagulation inhibits tumor cell-mediated release of platelet angiogenic proteins and diminishes platelet angiogenic response. Blood 2014;123:101–12.
   PubMed Web of Science ®Google Scholar
• Palumbo JS, Kombrinck KW, Drew AF, Grimes TS, Kiser JH, Degen JL, et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood 2000;96:3302–9.
   PubMed Web of Science ®Google Scholar
• Dvorak HF, Harvey VS, Estrella P, Brown LF, McDonagh J, Dvorak AM. Fibrin containing gels induce angiogenesis. Implications for tumor stroma generation and wound healing. Lab Invest 1987;57:673–86.
   PubMed Web of Science ®Google Scholar
• Schulman S, Rhedin AS, Lindmarker P, Carlsson A, Larfars G, Nicol P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995;332:1661–5.
   PubMed Web of Science ®Google Scholar
• Taliani MR, Agnelli G, Prandoni P, Becattini C, Moia M, Bazzan M, et al. Incidence of cancer after a first episode of idiopathic venous thromboembolism treated with 3 months or 1 year of oral anticoagulation. J Thromb Haemost 2003;1:1730–3.
   PubMed Web of Science ®Google Scholar
• Ahern TP, Pedersen L, Svaerke C, Rothman KJ, Sorensen HT, Lash TL. The association between vitamin K antagonist therapy and site-specific cancer incidence estimated by using heart valve replacement as an instrumental variable. Am J Epidemiol 2011;174:1382–90.
   PubMed Web of Science ®Google Scholar
• Tagalakis V, Tamim H, Blostein M, Collet JP, Hanley JA, Kahn SR. Use of warfarin and risk of urogenital cancer: a population-based, nested case-control study. Lancet Oncol 2007;8:395–402.
   PubMed Web of Science ®Google Scholar
• Pengo V, Noventa F, Denas G, Pengo MF, Gallo U, Grion AM, et al. Long-term use of vitamin K antagonists and incidence of cancer: a population-based study. Blood 2011;117:1707–9.
   PubMed Web of Science ®Google Scholar
• Pottegård A, Friis S, Hallas J. Cancer risk in long-term users of vitamin K antagonists: a population-based case-control study. Int J Cancer 2013;132:2606–12.
   PubMed Web of Science ®Google Scholar
• Tagalakis V, Tamim H. The effect of warfarin use on clinical stage and histological grade of prostate cancer. Pharmacoepidemiol Drug Saf 2010;19:436–9.
   PubMed Web of Science ®Google Scholar
• Blanc-Lapierre A, Weiss D, Parent ME. Use of oral anticoagulants and risk of prostate cancer: a population-based case-control study in Montreal, Canada. Cancer Causes Control 2014;25:1159–66.
   PubMed Web of Science ®Google Scholar
• Bobek V, Kovarik J. Antitumor and antimetastatic effect of warfarin and heparins. Biomed Pharmacother 2004;58:213–19.
   PubMed Web of Science ®Google Scholar
• Smorenburg SM, Van Noorden CJ. The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacol Rev 2001;53:93–105.
   PubMed Web of Science ®Google Scholar
• Im JH, Fu W, Wang H, Bhatia SK, Hammer DA, Kowalska MA, et al. Coagulation facilitates tumor cell spreading in the pulmonary vasculature during early metastatic colony formation. Cancer Res 2004;64:8613–19.
   PubMed Web of Science ®Google Scholar
• Kilpeläinen TP, Tammela TL, Malila N, Hakama M, Santti H, Määttänen L, et al. Prostate cancer mortality in the Finnish randomized screening trial. J Natl Cancer Inst 2013;105:719–25.
   PubMedGoogle Scholar
• Freedland SJ, Hamilton RJ, Gerber L, Banez LL, Moreira DM, Andriole GL, et al. Statin use and risk of prostate cancer and high-grade prostate cancer: results from the REDUCE study. Prostate Cancer Prostatic Dis 2013;16:254–9.
   PubMed Web of Science ®Google Scholar
• Hitron A, Adams V, Talbert J, Steinke D. The influence of antidiabetic medications on the development and progression of prostate cancer. Cancer Epidemiol 2012;36:e243–50.
   PubMed Web of Science ®Google Scholar
• Kemppainen KJ, Tammela TLJ, Auvinen A, Murtola TJ. The association between antihypertensive drug use and incidence of prostate cancer in Finland: a population-based case-control study. Cancer Causes Control 2011;22:1445–52.
   PubMed Web of Science ®Google Scholar
• Liu Y, Chen J, Xie L, Wang J, Li T, He Y, et al. Effect of aspirin and other non-steroidal anti-inflammatory drugs on prostate cancer incidence and mortality: a systematic review and meta-analysis. BMC Med 2014;12:55.
   PubMed Web of Science ®Google Scholar
• Mahmud SM, Franco EL, Aprikian AG. Use of nonsteroidal anti-inflammatory drugs and prostate cancer risk: a meta-analysis. Int J Cancer 2010;127:1680–91.
   PubMed Web of Science ®Google Scholar
• Martin RM, Vatten L, Gunnell D, Romundstad P. Blood pressure and risk of prostate cancer: cohort Norway (CONOR). Cancer Causes Control 2010;21:463–72.
   PubMed Web of Science ®Google Scholar
• Murtola TJ, Tammela TLJ, Maattanen L, Hakama M, Auvinen A. Prostate cancer risk among users of finasteride and alpha-blockers – a population based case-control study. Eur J Cancer 2007;43:775–81.
   PubMed Web of Science ®Google Scholar
• Nordstrom T, Clements M, Karlsson R, Adolfsson J, Gronberg H. The risk of prostate cancer for men on aspirin, statin or antidiabetic medications. Eur J Cancer 2015;51:725–33.
   PubMed Web of Science ®Google Scholar
• Preston MA, Wilson KM, Markt SC, Ge R, Morash C, Stampfer MJ, et al. 5α-Reductase inhibitors and risk of high-grade or lethal prostate cancer. JAMA Intern Med 2014;174:1301–7.
   PubMed Web of Science ®Google Scholar
• Robinson D, Garmo H, Bill-Axelson A, Mucci L, Holmberg L, Stattin P. Use of 5α-reductase inhibitors for lower urinary tract symptoms and risk of prostate cancer in Swedish men: nationwide, population based case-control study. BMJ 2013;346:f3406.
   Google Scholar
• Vidal AC, Howard LE, Moreira DM, Castro-Santamaria R, Andriole GL, Freedland SJ. Aspirin, NSAIDs, and risk of prostate cancer: results from the REDUCE study. Clin Cancer Res 2015;21:756–62.
   PubMed Web of Science ®Google Scholar
• Wang X, Lin Y, Wu J, Zhu Y, Xu XL, Xu X, et al. Meta-analysis of nonsteroidal anti-inflammatory drug intake and prostate cancer risk. World J Surg Oncol 2014;12:304.
   PubMed Web of Science ®Google Scholar
• Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008;371:569–78.
   PubMed Web of Science ®Google Scholar
• Bhaskaran K, Douglas I, Forbes H, dos-Santos-Silva I, Leon DA, Smeeth L. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5·24 million UK adults. Lancet 2014;384:755–65.
   PubMed Web of Science ®Google Scholar
• Islami F, Moreira DM, Boffetta P, Freedland SJ. A systematic review and meta-analysis of tobacco use and prostate cancer mortality and incidence in prospective cohort studies. Eur Urol 2014;66:1054–64.
   PubMed Web of Science ®Google Scholar